Mark Engel | CEO
Phagelux

Mark Engel, CEO, Phagelux

Mark has been founding and building life sciences companies in China since 1990 including most recently Phagelux which develops antibacterial products for multiple industries, particularly focusing on antibiotic resistant strains.
Mark is also the co-founder and director of Haoyisheng which is a leading Chinese professional healthcare technology group company.
Previously built companies include: (1) NPO Pharmaceuticals (sold in 1999) and at the time a leading “multinational” pharma company in China; (2) Excel PharmaStudies (sold in late 2009 to PPD) and at the time the largest clinical research organization in China with additional operations throughout Asia; and (3) Tiger Medical Group (merged with ASP Global in 2013), a distributor of about 800 branded medical products from Asia to institutional buyers worldwide.
Mark’s fund Tianshi Capital is also an investor in China life sciences companies including: (1) animal vaccines; (2) medical devices and (3) agri/aquaculture technologies.

Appearances:



World Anti-Microbial Resistance Congress USA 2018 - Day 2 @ 11:30

Utilizing bacteriophages to prevent infections

    Traditionally companies and institutes have tried to develop bacteriophages as therapiesCommercial realties of therapies vs. preventatives
  • Phagelux Solutions: sustained release sprays and patches
last published: 18/Oct/18 13:55 GMT

back to speakers